Search for: "Teva Pharmaceuticals"
Results 921 - 940
of 1,429
Sort by Relevance
|
Sort by Date
1 Jun 2011, 4:54 pm
Teva Pharmaceuticals USADocket: 10-1070Issue(s): When a case becomes moot as the result of a third party’s independent action after the court of appeals issues a judgment but while a petition for rehearing is still pending, should the court of appeals vacate the judgment upon the request of the aggrieved party? [read post]
31 May 2011, 8:38 pm
Merial (EPLAW) Neurontin (Gabapentin) – US: Teva settles Pfizer case on generic epilepsy drug with undisclosed terms (GenericsWeb) Noxafil (Posaconazole) – US: Schering files patent infringement complaint against Sandoz in response to Para IV certification (Patent Docs) Patanol (Olopatadine) – US: Alcon wins Patanol patent infringement lawsuit against Apotex (GenericsWeb) Prandin (Repaglinide) – US: Obama Administration urges Supreme Court to grant certiorari in case… [read post]
Obama Administration Urges Supreme Court to Grant Certiorari in Case on Orange Book Patent Use Codes
30 May 2011, 9:49 pm
PIRG; the Generic Pharmaceutical Association (GPhA); Mylan; and Teva. [read post]
27 May 2011, 8:56 am
”Certiorari stage documents:Opinion below (3d Circuit)Petition for certiorariBrief in oppositionPetitioners' replyAmicus brief of TEVA Pharmaceuticals USA, Inc.Amicus brief of Consumer Federation of America et al.Amicus brief of Mylan Pharmaceuticals, Inc.Amicus brief of Apotex, Inc.Amicus Generic Pharmaceutical AssociationCVSG Information:Invited: March 28, 2011Filed: May 26, 2011 (Grant) Title: National Meat Association v. [read post]
25 May 2011, 8:52 pm
From the pharmaceutical industry, amicus briefs were filed by Apotex; Sanofi-Aventis; Eli Lilly & Co.; BIO; Eisai; Johnson & Johnson; PhRMA; Teva; and GPhA. [read post]
25 May 2011, 4:59 am
(Kluwer Patent Blog) USPTO statement at WIPO side event on Medicines Patent Pool (Knowledge Ecology International) US: To implement health reform orphan drug exclusion, HRSA issues first-ever proposed regulation on 340B drug discount program (FDA Law Blog) US: FDA officials hint at provisions of biosimilar guidances (Patent Docs) US: Huffington Post: Data Exclusivity: Getting the balance right (PatentlyBIOtech) US: Report gauges economic impact of Human Genome Project (Patent Docs) US: Chairman… [read post]
23 May 2011, 11:47 pm
Teva Pharmaceuticals USADocket: 10-1070Issue(s): When a case becomes moot as the result of a third party’s independent action after the court of appeals issues a judgment but while a petition for rehearing is still pending, should the court of appeals vacate the judgment upon the request of the aggrieved party? [read post]
23 May 2011, 9:59 pm
• Defendants: Impax Laboratories, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd. [read post]
23 May 2011, 9:52 pm
Teva Pharmaceuticals USADocket: 10-1070Issue(s): When a case becomes moot as the result of a third party’s independent action after the court of appeals issues a judgment but while a petition for rehearing is still pending, should the court of appeals vacate the judgment upon the request of the aggrieved party? [read post]
23 May 2011, 4:00 am
Teva Pharmaceuticals USA Inc., 2011 U.S. [read post]
22 May 2011, 8:41 pm
• Defendant: Teva Pharmaceuticals USA, Inc. [read post]
18 May 2011, 12:33 am
Sun Pharmaceuticals on question of obviousness-type double patenting (Patent Docs) (IPBiz) Glumetza (Metformin) – US: Depomed receives notice of Para IV certification against patents from second ANDA filer, Sun Pharmaceutical (GenericsWeb) Myfortic7 (Mycophenolate) – US: Novartis files patent infringement complaint against Teva in response to Para IV certification filing (Patent Docs) NuvaRing (Etonogestrel, Estradiol) – US: ALJ Luckern sets procedural… [read post]
17 May 2011, 11:53 pm
The first generic version was called Gianvi, and was launched by Teva Pharmaceuticals in June 2010. [read post]
15 May 2011, 8:55 pm
• Defendant: Teva Pharmaceuticals USA Inc. [read post]
11 May 2011, 4:54 am
ARUP: Genetic testing patents found to be anticipated and in violation of Lilly written description requirement (Holman’s Biotech IP Blog) (Patent Docs) (Patently-O) US: FDA gets the ball rolling on biosimilar/interchangeable biological product user fee program; proposal gives a hat tip to PDUFA while acknowledging the nascent state of the industry (FDA Law Blog) (Patent Docs) Products Citalopram – UK Patents Court disapproving of EPO’s approach to assessment of novelty: Lundbeck v… [read post]
10 May 2011, 11:59 pm
Wyeth has also reached agreements with other companies as well, including Sun Pharma, Lupin, Aurobindo Pharma, Ranbaxy and Teva. [read post]
7 May 2011, 1:37 am
(Generic Pharmaceuticals and IP) Wikileaks cables show massive U.S. effort to establish Canadian DMCA / ?????????????????????????????????? [read post]
6 May 2011, 3:00 am
Fox and Symons led Kirkland's team advising Teva Pharmaceuticals on its $6.8 billion acquisition of Cephalon, Inc. [read post]
6 May 2011, 2:00 am
Ocella is the generic form, which is marketed and distributed by Teva Pharmaceuticals, and was approved by the FDA in 2008. [read post]
5 May 2011, 11:08 pm
The various plaintiffs in the case have filed their lawsuits against the brand name makers of Reglan, Wyeth and Schwarz Pharma, as well as the makers of the generic versions like Teva Pharmaceuticals and Pliva Inc. [read post]
